Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01143779 · ClinicalTrials.gov registry record · Phase 1
FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib
A Phase 1 study of Advanced Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT01143779: Completed Phase 1 study of Advanced Cancer, sponsored by M.D. Anderson Cancer Center.
NCT01143779 is a Phase 1 study of Advanced Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01143779, a Phase 1 study of Advanced Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if an imaging solution, \[F-18\]-fluoro-L-thymidine (FLT), when used with a positron emission tomography (PET) scan, can help doctors to better see changes in the growth of tumors in the body. Researchers want to learn if FLT-PET scans can show an early response to chemotherapy.
Primary Outcome
SUV measured on continuous scale at two specified time points (baseline and post-treatment phase, cycle 1, day 19-21).
Conditions Studied
Interventions
- DRUG FLT-PET
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2010-06 |
| Est. Completion | 2021-12-27 |
| Phase | Phase 1 |
What the finished NCT01143779 record still lists
NCT01143779 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which FLT-PET is the first listed.
NCT01143779 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01143779 about?
NCT01143779 is a clinical study titled "FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib". The goal of this clinical research study is to learn if an imaging solution, \[F-18\]-fluoro-L-thymidine (FLT), when used with a positron emission tomography (PET) scan, can help doctors to better see changes in the growth of tumors in the body. Researchers want to learn if FLT-PET scans can show an...
What is the current status of trial NCT01143779?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2010-06. Estimated completion is 2021-12-27.
What conditions does trial NCT01143779 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT01143779?
The interventions under investigation include: FLT-PET (DRUG).
Who is sponsoring clinical trial NCT01143779?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01143779 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01143779's enrollment target sits among peer trials
3 122nd of 122 higher than 1 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia